Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Ovarian germ cell tumor
Stage/Subtype:  stage IV ovarian germ cell tumor
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 30 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140053, 14-C-0053, NCT02054104
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000065903, UTHSC-MS-96205, NCI-V97-1356, NCT00003135
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 69
Sponsor: Other
Protocol IDs: 2006LS032, UMN-MT2005-21, UMN-0608M90586, UMN-2006LS032, NCT00432094
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 03909, NCI-2009-01467, NCT01037790
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 19 to 79
Sponsor: Other
Protocol IDs: UMCC 2011.037, HUM 47900, NCT01579812
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IUCRO-0403, NCI-2013-00510, 1301010501, NCT01808534
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 77
Sponsor: NCI, Other
Protocol IDs: IRB13-1235, NCI-2014-00860, UC IRB13-1235, P30CA014599, NCT02122185
Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 116911, NCT02340845
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 150112, 15-C-0112, NCT02417753
Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ATDTRPST0802, NCT00800345
Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HP-00040420, GCC 0805, NCT01110226
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED10499, U1111-1116-4129, 2011-003891-35, NCT01156870
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110061, 11-C-0061, NCT01273168
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA216-001, NCT01292655
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110148, 11-C-0148, NCT01341496
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02500, CDR0000700997, UPCI-10-115, 8808, P30CA047904, U01CA062490, U01CA062502, U01CA062505, U01CA069856, U01CA070095, U01CA099168, UM1CA186690, UM1CA186691, UM1CA186709, UM1CA186717, NCT01366144
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-09138, NCI-2011-00920, NCT01376505
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP27772, 2011-003394-28, NCT01494688
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and 0ver
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMGN853-0401, NCT01609556
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-A-007-13, NCT01831089
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GEN701, NCT02001623
A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 69
Sponsor: Other
Protocol IDs: Thermalcore-01, NCT02093871
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B7401001, NCT02122146
MLN0128 and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01107, 2013-0665, 9585, P30CA016672, U01CA062461, UM1CA186688, NCT02159989
Start Over